CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day.

CRISPR Therapeutics (NASDAQ:CRSP) traded higher in the premarket on Thursday after J.P. Morgan initiated its coverage with an Overweight recommendation, noting how the company stands out in the gene ...

Detailed price information for Ark Innovation ETF (ARKK-A) from The Globe and Mail including charting and trades.

The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.